An International Study on Pediatric Patients With Rare Tumors.
NCT ID: NCT07072143
Last Updated: 2025-07-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
6250 participants
OBSERVATIONAL
2025-01-25
2049-06-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
NCT01294670
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
NCT02104986
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
NCT04901702
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
NCT02914405
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
NCT02982941
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of this study is to collect epidemiological, clinical, biological, radiological and treatment data on children and adolescents with rare cancers in order to improve our understanding of these tumors and how their clinical and biological characteristics affect treatment outcomes.
Due to the rarity of these malignancies, international collaboration is necessary to collect sufficient data on each tumour type.
While the investigators are not proposing specific treatments, the data collected will inform recommendations for the diagnosis and treatment of patients.
The PARTNER Study is an observational, prospective study. It is sponsored by Padua University Hospital AOUP (Italy), and all European centres collaborating with the EXPeRT group have been invited to participate. It is a non-profit study, meaning it has no commercial purpose, only the aim of improving knowledge and treatment for children with rare cancers. PARTNER activities are supported in different countries by national funds, as well as by the European Commission through the European Reference Network for Paediatric Oncology (ERN PaedCan). Please visit https://paedcan.ern-net.eu/ for more information.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent from the patient and/or the parent/legal guardian
Exclusion Criteria
0 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Anna Children's Hospital, Vienna
UNKNOWN
Children's Hospital Zagreb
OTHER
Centre Hospitalier Universitaire de La Réunion, FRANCE
UNKNOWN
Klinikum Dortmund
UNKNOWN
University Children's Hospital Tuebingen
OTHER
Hellenic Oncology Research Group
OTHER
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER
Kaplan Medical Center, Rehovot, Israel
UNKNOWN
Vilnius University hospital Santaros klinikos, Vilnius, Lithuania
UNKNOWN
University of Skopje
OTHER
Gdansk Medical University (Poland)
UNKNOWN
Centro Hospitalar do Porto
OTHER
Bucharest Emergency Hospital
OTHER
Institute for Oncology and Radiology Serbia, Belgrade
UNKNOWN
University Hospital Bratislava
OTHER
University Medical Centre Ljubljana
OTHER
University of Bilbao
UNKNOWN
Göteborg University
OTHER
University Hospital, Paris
OTHER
Azienda Ospedaliera di Padova
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gianni Bisogno
Professor of Paediatrics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gianni Bisogno, MD
Role: PRINCIPAL_INVESTIGATOR
Azienda Ospedale Università Padova - Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pediatric Oncology Unit, University Hospital Padova [AOUP Azienda Ospedale Università Padova]
Padua, Italy, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Orbach D, Ferrari A, Schneider DT, Reguerre Y, Godzinski J, Bien E, Stachowicz-Stencel T, Surun A, Almaraz RL, Dragomir M, Jani D, Ami TB, Roganovic J, Brecht IB, Ladenstein R, Bisogno G. The European Paediatric Rare Tumours Network - European Registry (PARTNER) project for very rare tumors in children. Pediatr Blood Cancer. 2021 Jun;68 Suppl 4:e29072. doi: 10.1002/pbc.29072. Epub 2021 Apr 29.
Related Links
Access external resources that provide additional context or updates about the study.
The page describes the PARTNER project inside the website of SIOP Europe (the European Society for Paediatric Oncology)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
The PARTNER study (AOP3417)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.